Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Littelfuse makes a variety electrical components that are used in the auto, computer and other industries. The company has facilities around the world, but is based in Chicago.
Raising Guidance
One of the best events that can happen for a stock is to have the company raise guidance ahead of an earnings report. On Jun 11 Littelfuse did just that, lifting its sales forecasts by $7 million on both ends of the range, to between $155 and $160 million.
The CEO sited increasing demand and the companys rapid response to meet the growing orders. Littelfuse also has a solid backlog of orders moving forward.
Estimates Climb
Following the revised guidance analysts began raising estimates. The Zacks Consensus Estimate for 2010 is up 22 cents to $3.14. Next year's forecasts are averaging $3.39, up 17 cents.
Littelfuse is in the midst of a big comeback after earning just 61 cents in 2009.
Valuations
No matter what metric you are looking at, the valuations for LFUS are attractive. The forward P/E is just 10 times and the PEG ratio is a solid 1.0. Currently the price-to-book is slightly higher than the industry average but only 1.7 times.
Littelfuse is well ahead of its peers in terms on profitability as well. The net profit margin is about 6.7% compared to the industry average of 1.0%. Littelfuse produces a return on equity of just under 10%, more than twice the industry norm.
The Chart
Shares of LFUS had been in a sharp downward trend until the revised guidance. While shares have sold off since the jump on the news, the announcement was enough to slow the bleeding and should spark a turn around heading into the company's next earnings release.
Bill Wilton is the Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the market-beating Zacks Growth Trader service
Read the full Snapshot Report on LFUS